Table 2.

PD-L1 expression levels in available samples

HS, n (%)
Treatment01–56–1011–2526–50≥50Total
Pazopanib142 (64)17 (7)12 (5)9 (4)14 (6)27 (12)221
Sunitinib148 (64)15 (6)7 (3)16 (7)12 (5)34 (15)232